Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial

Introduction A December 2019 WHO rapid communication recommended the use of 9-month all-oral regimens for treating multidrug-resistant tuberculosis (MDR-TB). Besides the clinical benefits, they are thought to be less costly than the injectable-containing regimens, for both the patient and the health...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Bruce Kirenga, Andrew Nunn, Ewan Tomeny, Jason Madan, Bertel Squire, Laura Rosu, Eve Worrall, Mamo Girma, Vanita Patel, Makwana Mukesh, Malaisamy Muniyandi, Shravan Kumar, Sangeetha Subramani, Saleem Ahmad, Jasper Nidoi, Irina Pirlog, Mariana Macarie, ID Rusen, Gay Bronson, Meera Gurumurthy, Karen Sanders, Sarah Meredith, Wendy Dodds Ben Spittle, Robyn Henry-Cockles, Rachel Bennett, Elisa Giallongo, Danni Maas, Ruth Goodall, Saiam Ahmed, Claire Cook, Katharine Bellenger, Gopalan Narendran, Elena Tudor, Rajesh Solanki, Daniel Meressa, Adamu Bayissa, Anuj Bhatnagar
Format:	article
Langue:	EN
Publié:	BMJ Publishing Group 2020
Sujets:	Medicine R
Accès en ligne:	https://doaj.org/article/a9fcc9bd4f9a4b70a682711333f0f708
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial

Documents similaires